Overcoming challenges in gene therapy IND-submissions

April 23rd, 2020 • 11 a.m. PST, 2 p.m. EST

Sign Up:

(*) denotes required form field(s)

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.



The webinar will focus upon the common issues which might delay the IND submission or pre-IND interaction with FDA. We will discuss how to design your in-vitro or in-vivo studies timely and effectively to overcome these issues, with a view toward current regulatory guidelines and the expectations of regulatory agencies.

In this webinar you’ll learn: 

  • Common roadblocks & mitigation strategies
  • Designing studies effectively and efficiently
  • Compiling the IND package & interactions with FDA

Who should attend?

  • Scientists, Postdoctoral fellows, PIs (Cell & Molecular Biologist)
  • Project/Account Managers
  • Regulatory personnel
  • CGT start-up aspirants


Mike Auerbach
American Pharmaceutical Review
Vibhor Gupta, Ph.D.
Director of Business Operations, Cell and Gene Therapy
Absorption Systems
View Biography